Vital pulpotomy in the primary dentition: attitudes and practices of community dental staff in Wales.
OBJECTIVE
The International Agency for Research on Cancer (IARC) has classified formaldehyde as carcinogenic to humans, leaving the dental profession to look for viable substitutes to formocresol in the vital pulpotomy technique. This study was designed to examine the attitudes and practices of Community Dental Service (CDS) staff in Wales in relation to vital pulpotomy for primary molars 18 months following the IARC's press release.


METHODS
The study employed a postal questionnaire.


RESULTS
Questionnaires were returned by 79 (78.2%) of the CDS staff surveyed, yielding a sample of 65 dentists practising the technique. The most commonly used pulpotomy agents were formocresol, paraformaldehyde and ferric sulphate. Twenty-seven (41.5%) dentists expressed concern regarding their preferred pulpotomy agent and 17 (26.2%) were considering changing their technique. Only one respondent (1.5% of the sample) routinely took preoperative radiographs; follow-up radiographs were routinely taken by only three dentists (4.6%). Only 44 respondents (67.7%) always used local anaesthesia for this form of treatment. Amalgam was the most commonly used restorative material. Twenty-two respondents (33.8%) stated that they would pulp treat a primary molar on more than one occasion.


CONCLUSIONS
The results of this study suggest that there is need for relevant continuing professional development courses for CDS staff in Wales.
Hingston
Emma Jane
EJ
Dental Health and Biological Sciences, Wales College of Medicine, School of Dentistry, Cardiff, UK.
Parmar
Sharlene
S
Hunter
Margaret Lindsay
ML
D000772:Anesthesia, Local; D001291:Attitude of Health Personnel; D003149:Community Dentistry; D020770:Compomers; D003723:Dental Amalgam; D003782:Dental Pulp / Q000000981:diagnostic imaging; D003793:Dental Restoration, Permanent / Q000379:methods; D003815:Dentists / Q000523:psychology*; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use; D005557:Formaldehyde / Q000627:therapeutic use; D005566:Formocresols / Q000627:therapeutic use; D005899:Glass Ionomer Cements; D006801:Humans; D008297:Male; D008963:Molar / Q000473:pathology; D010486:Periapical Tissue / Q000000981:diagnostic imaging; D011108:Polymers / Q000627:therapeutic use; D019239:Practice Patterns, Dentists'; D011672:Pulpotomy / Q000379:methods*; D011859:Radiography; D014094:Tooth, Deciduous / Q000473:pathology*; D014852:Wales; D000078329:Workforce
D020770:Compomers; D005290:Ferric Compounds; D005566:Formocresols; D005899:Glass Ionomer Cements; D011108:Polymers; D005557:Formaldehyde; C031025:formocresol; C024823:ferric sulfate; D003723:Dental Amalgam; C003043:paraform